<DOC>
	<DOCNO>NCT01193361</DOCNO>
	<brief_summary>At least 1 dose BMS-791325 identify safe , well tolerate , efficacious combine peg-interferon alfa-2a ( pegIFNα-2a ) /ribavirin ( RBV ) treatment treatment-naïve , chronically-infected hepatitis C virus ( HCV ) genotype 1 subject</brief_summary>
	<brief_title>Ph IIA Study ( SOC +/- NS5B )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Subjects chronically infect HCV genotype 1 document : positive antiHCV antibody , HCV RNA , positive HCV genotype test least 6 month prior Screening , positive HCV RNA antiHCV antibody Screening HCV RNA ≥ 10*5* IU/mL Screening Less 4 week total prior therapy IFN formulation ( ie , IFNα , pegIFNα2a ) , RBV exposure IFN RBV within 24 week Randomization Results biopsy obtain ≤ 24 month prior Randomization show evidence cirrhosis Body Mass Index ( BMI ) 18 35 kg/m² , inclusive . BMI = weight ( kg ) / [ height ( ) ] ² Screening Liver transplant recipient Documented suspected HCC image liver biopsy Evidence medical condition associate chronic liver disease HCV ( limited : hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History chronic hepatitis B virus ( HBV ) document HBV serology ( eg . HBsAgseropositive ) . Patients resolve HBV infection may participate ( eg . HBsAbseropositive ) Current know history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>